STOCK TITAN

Herbalife (NYSE: HLF) CLO corrects SAR exercise price in Form 4/A

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

HERBALIFE LTD. Chief Legal Officer Henry C. Wang reported an amended Form 4 reflecting a grant of 33,301 stock appreciation rights. The amendment corrects a previously reported exercise price of $10.51. These SARs were granted under the company’s Amended and Restated 2023 Stock Incentive Plan and will vest in three equal installments on February 25, 2027, February 25, 2028, and February 25, 2029, subject to continued service.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wang Henry C

(Last) (First) (Middle)
800 WEST OLYMPIC BLVD.
SUITE 406

(Street)
LOS ANGELES CA 90015

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
HERBALIFE LTD. [ HLF ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Legal Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
02/27/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Appreciation Rights $19.26(1) 02/25/2026 A 33,301 (2) 02/25/2036 Common Stock 33,301 $0 33,301 D
Explanation of Responses:
1. This amendment is being filed solely to correct the exercise price, which was previously reported as $10.51. No other information in the original Form 4 has been changed.
2. Consists of stock appreciation rights ("SARs") granted under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan. These SARs will vest in one-third increments on each of February 25, 2027, February 25, 2028, and February 25, 2029, subject to continued service through such date.
/s/ Alaaeddine Sahibi, as Attorney-In-Fact for Henry C. Wang 03/03/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Herbalife (HLF) report for Henry C. Wang?

Herbalife reported an amended Form 4 for Chief Legal Officer Henry C. Wang, reflecting a grant of 33,301 stock appreciation rights. The filing updates a previously incorrect exercise price and confirms these awards under the Amended and Restated 2023 Stock Incentive Plan.

Why did Herbalife (HLF) file an amended Form 4 for Henry C. Wang?

The amended Form 4 was filed solely to correct the exercise price of previously reported stock appreciation rights. The original filing listed an exercise price of $10.51, and no other information about the award or holdings was changed in this amendment.

How many stock appreciation rights were granted to Herbalife (HLF) executive Henry C. Wang?

Henry C. Wang received a grant of 33,301 stock appreciation rights. These derivative awards were reported at a transaction price of $0.0000 per right and are held directly, with 33,301 rights reported as beneficially owned following the transaction.

What plan governs the stock appreciation rights granted to Herbalife (HLF) CLO Henry C. Wang?

The stock appreciation rights granted to Henry C. Wang were issued under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan. This equity plan authorizes awards such as SARs to executives as part of their long-term incentive compensation structure.

What is the vesting schedule for Henry C. Wang’s Herbalife (HLF) stock appreciation rights?

The 33,301 stock appreciation rights will vest in three equal one-third installments. Vesting dates are February 25, 2027, February 25, 2028, and February 25, 2029, and each tranche requires Henry C. Wang’s continued service with Herbalife through the applicable vesting date.

Did the amended Herbalife (HLF) Form 4 change any details besides the exercise price?

No, the amendment states it was filed solely to correct the exercise price, previously reported as $10.51. All other information from the original Form 4, including the number of stock appreciation rights and vesting terms, remains unchanged according to the disclosure.
Herbalife

NYSE:HLF

HLF Rankings

HLF Latest News

HLF Latest SEC Filings

HLF Stock Data

1.83B
101.38M
Packaged Foods
Wholesale-drugs, Proprietaries & Druggists' Sundries
Link
United States
GEORGE TOWN